(Q54520157)

30 May 2018

title

Association of ABCB1 polymorphisms with erlotinib pharmacokinetics and toxicity in Japanese patients with non-small-cell lung cancer. (English)

1 reference

30 May 2018

1 reference

Akinobu Hamada

1

1 reference

30 May 2018

Ji-Ichiro Sasaki

2

1 reference

30 May 2018

Sho Saeki

3

1 reference

30 May 2018

Norihiro Iwamoto

4

1 reference

30 May 2018

Megumi Inaba

5

1 reference

30 May 2018

Sunao Ushijima

6

1 reference

30 May 2018

Maki Urata

7

1 reference

30 May 2018

Hiroto Kishi

8

1 reference

30 May 2018

Shinji Fujii

9

1 reference

30 May 2018

Hiroshi Semba

10

1 reference

30 May 2018

Kosuke Kashiwabara

11

1 reference

30 May 2018

Yukari Tsubata

12

1 reference

30 May 2018

Yuki Kai

13

1 reference

30 May 2018

Takeshi Isobe

14

1 reference

30 May 2018

Hirotsugu Kohrogi

15

1 reference

30 May 2018

Hideyuki Saito

16

1 reference

30 May 2018

publication date

1 April 2012

1 reference

30 May 2018

published in

Pharmacogenomics

1 reference

30 May 2018

volume

13

1 reference

30 May 2018

issue

5

1 reference

30 May 2018

page(s)

615-624

1 reference

30 May 2018

Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer

cites work

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.176

EGFR mutation and response of lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.176

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.176

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.176

Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.176

Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.176

Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.176

Pharmacogenomics--drug disposition, drug targets, and side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.176

Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.176

Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.176

Concise review: Clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.176

Multidrug resistance in cancer: role of ATP-dependent transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.176

Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.176

Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.176

Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.176

A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.176

MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.176

Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.176

Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.176

Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein)

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.176

A "silent" polymorphism in the MDR1 gene changes substrate specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.176

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.176

Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.176

Liquid-chromatographic determination of erlotinib (OSI-774), an epidermal growth factor receptor tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.176

Common ATP-binding cassette B1 variants are associated with increased digoxin serum concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.176

P-glycoprotein (ABCB1) expression in human skin is mainly restricted to dermal components.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.176

ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.176

A variant 2677A allele of the MDR1 gene affects fexofenadine disposition.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.176

Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.176

Genetic polymorphisms in MDR1 and CYP3A5 and MDR1 haplotype in mainland Chinese Han, Uygur and Kazakh ethnic groups

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.176

Identification of functionally variant MDR1 alleles among European Americans and African Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.176

Genomic evidence for recent positive selection at the human MDR1 gene locus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.176

Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.176

ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.176

Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.176

Impact of cellular folate status and epidermal growth factor receptor expression on BCRP/ABCG2-mediated resistance to gefitinib and erlotinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.176

Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.176

Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.176

Serum concentrations of Erlotinib at a dose of 25 mg daily.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.176

Common germline MDR1/ABCB1 functional polymorphisms and haplotypes modify susceptibility to colorectal cancers with high microsatellite instability

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.176

21 January 2018

Identifiers

DOI

10.2217/PGS.11.176

1 reference

30 May 2018

1 reference

30 May 2018